Adrenal Tumors - Pathogenesis and Therapy | NCT00669266

Studies
Adrenal Tumors - Pathogenesis and Therapy

NCT00669266

Sponsor

University of Wuerzburg

Status

Recruiting

Last Update Posted

May 7, 2026Actual

Enrollment

500Estimated

Phase

Not provided

Conditions

Adrenal Tumors
Adrenocortical Carcinoma
Cushing Syndrome
Conn Syndrome
Pheochromocytoma

Interventions

Not provided

Countries

Germany

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

May 2026

Overall Recruitment Status or Expanded Access Status

Recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Sep 2002Actual

Primary Completion Date

Dec 2030Estimated

Completion Date

Dec 2032Estimated

First Submitted Date

Apr 28, 2008

First Submission Date that Met QC Criteria

Apr 29, 2008

First Posted Date

Apr 30, 2008Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

May 1, 2026

Last Update Posted Date

May 7, 2026Actual

Sponsor/Collaborators Module

Responsible Party, by Official Title

Martin Fassnacht, Head of Endocrinology, University of WuerzburgPrincipal Investigator

Lead Sponsor

University of WuerzburgOTHER

Collaborators

Name	Class
Deutsche Krebshilfe e.V., Bonn (Germany)	OTHER
German Federal Ministry of Education and Research	OTHER_GOV

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.

Detailed Description

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

Retention

Enrollment

500Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Tumor		Tumor material and corresponding biosamples from patients with adrenal tumors
control group		Biomaterial from patients without adrenal tumor

Interventions

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

adrenal tumor detected by imaging

Exclusion Criteria:

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

Not provided

Maximum Age

100 Years

Standard Ages

ChildAdultOlder Adult

Study Population

Patients with adrenal tumors

Sampling Method

Non-Probability Sample

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Martin Fassnacht, MD	Contact	49-931-201-36507		fassnacht_m@medizin.uni-wuerzburg.de

Overall Officials

Name	Affiliation	Role
Martin Fassnacht, MD	U of Wuerzburg	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
University of Wuerzburg	Recruiting	Würzburg		97080	Germany

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
35583844	Result	Tamburello M, Altieri B, Sbiera I, Sigala S, Berruti A, Fassnacht M, Sbiera S. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. Endocrine. 2022 Sep;77(3):411-418. doi: 10.1007/s12020-022-03074-z. Epub 2022 May 18.
34956100	Result

ID	Term
D000310	Adrenal Gland Neoplasms
D018268	Adrenocortical Carcinoma
D003480	Cushing Syndrome
D006929	Hyperaldosteronism
D010673	Pheochromocytoma

ID	Term
D004701	Endocrine Gland Neoplasms
D009371	Neoplasms by Site
D009369	Neoplasms
D000307	Adrenal Gland Diseases